研究单位：[1]Chinese Academy of Medical Sciences[2]Beijing Hospital[3]Jiangsu Cancer Institute & Hospital[4]The Affiliated Hospital of Qingdao University[5]Shanxi Province Cancer Hospital[6]Affiliated Hospital of Hebei University[7]Shandong Cancer Hospital and Institute[8]The First Affiliated Hospital of Zhengzhou University[9]Hebei Medical University Fourth Hospital[10]First Hospital of China Medical University[11]Cancer Hospital,Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[12]National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College,Beijing,China,100021
研究目的：
This is a multi-center, retrospective, real-world study. The purpose of this study is to observe the effectiveness and safety of regorafenib in Chinese advanced colorectal cancer patients. The main observational goals include overall survival(OS), 6 month OS rate, 1 year OS rate, and treatment time failure (TTF), other study goals include objective response rate( ORR)、Disease control rate（DCR）and adverse event(AE) of regorafenib.
